NASDAQ
168.67USD
-6.68 (-3.81%)
We have scored 9 news catalysts on Belite Bio, Inc (BLTE) over the past 12 months. The biggest single-day move next to one of them came Sep 4, 2026, when BLTE closed +13.2%: “Why Is Belite Bio Stock Soaring Friday?”. Coverage across the window leans positive (average ticker sentiment +0.69). Most of the impact sits in short squeeze potential and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.8B
P/E
—
EPS
—
Beta
-1.24
52W range
68.21-200
Day range
166.60–175.50
Open
175.50
Prev close
175.35
Volume
107.1K
Avg volume
206.8K
Dividend
0.00
IPO
2022-04-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Belite Bio, Inc — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BLTE: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
